Still, the magnitude of Bcl-2 prognostic impact observed here in metastatic versus non-metastatic BC had not been previously revealed [49], supporting a critical value of correlated evaluation of malignancy determinants (Bcl-2, p53, cathepsin D) for effective use in prognostic assessment. This evidence concerns the gene BCL2 and breast cancer.